Nkarta Inc
NASDAQ:NKTX

Watchlist Manager
Nkarta Inc Logo
Nkarta Inc
NASDAQ:NKTX
Watchlist
Price: 2.42 USD 2.98% Market Closed
Market Cap: 170.8m USD
Have any thoughts about
Nkarta Inc?
Write Note

EV/EBITDA
Enterprise Value to EBITDA

0.9
Current
-0.6
Median
4.3
Industry
Higher than median
Lower than industry value

Enterprise Value to EBITDA (EV/EBITDA) ratio is a valuation multiple that compares the value of a company, debt included, to the company’s cash earnings less non-cash expenses. EBITDA can be misleading at times, especially for companies that are highly capital intensive.

EV/EBITDA
0.9
=
Enterprise Value
-112.3m USD
/
EBITDA
-119.3m USD
All Countries
Close
Market Cap EV/EBITDA
US
Nkarta Inc
NASDAQ:NKTX
170.8m USD 0.9
FR
Pharnext SCA
OTC:PNEXF
6T USD -219 636.3
US
Abbvie Inc
NYSE:ABBV
314.6B USD 15.4
US
Amgen Inc
NASDAQ:AMGN
141.2B USD 16
US
Gilead Sciences Inc
NASDAQ:GILD
117.2B USD 10.3
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
105.4B USD 21.7
US
Epizyme Inc
F:EPE
94.1B EUR -514.4
AU
CSL Ltd
ASX:CSL
136.4B AUD 19.9
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
78.4B USD 15.3
US
Seagen Inc
F:SGT
39.3B EUR -58.7
NL
argenx SE
XBRU:ARGX
36.2B EUR -110
EBITDA Growth EV/EBITDA to Growth
US
Nkarta Inc
NASDAQ:NKTX
Average EV/EBITDA: 14.2
0.9
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -219 636.3 N/A N/A
US
Abbvie Inc
NYSE:ABBV
15.4
9%
1.7
US
Amgen Inc
NASDAQ:AMGN
16
18%
0.9
US
Gilead Sciences Inc
NASDAQ:GILD
10.3
5%
2.1
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
21.7
13%
1.7
US
E
Epizyme Inc
F:EPE
Negative Multiple: -514.4 N/A N/A
AU
CSL Ltd
ASX:CSL
19.9
12%
1.7
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
15.3
11%
1.4
US
S
Seagen Inc
F:SGT
Negative Multiple: -58.7 N/A N/A
NL
argenx SE
XBRU:ARGX
Negative Multiple: -110 N/A N/A

EV/EBITDA Forward Multiples

Forward EV/EBITDA multiple is a version of the EV/EBITDA ratio that uses forecasted EBITDA for the EV/EBITDA calculation. 1-Year, 2-Years, and 3-Years forwards use EBITDA forecasts for 1, 2, and 3 years ahead, respectively.

1-Year Forward
EV/EBITDA
0.9
2-Years Forward
EV/EBITDA
0.8
3-Years Forward
EV/EBITDA
0.7

See Also

Discover More